drugset / Trial / NCT04292119
Lorlatinib Combinations in Lung Cancer
Phase 1/2
Unknown
96 enrolled
Massachusetts General Hospital
Array BioPharma · collabPfizer · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. * This research study involves four study drugs. * Lorlatinib * Binimetinib * Crizotinib * TNO155
Timeline
- Start
- 2020-05-01
- Primary completion
- 2022-12-01
- Completion
- 2023-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BATOPROTAFIB | Small molecule | — | Oral |
| Subject | Binimetinib | Small molecule | — | Oral |
| Subject | Crizotinib | Small molecule | — | Oral |
| Subject | Lorlatinib | Small molecule | — | Oral |